All lobbying filings

The McManus Group

The McManus Group filed a Q1 report for Fulcrum Therapeutics on April 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Fulcrum Therapeutics · Rare disease biopharma company

As filed: THE MCMANUS GROUP for FULCRUM THERAPEUTICS.

All filings by The McManus Group · Everything Fulcrum Therapeutics has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025. Priority review vouchers: Give Kids a Chance Act of 2025 (H.R. 1262/S.932) Issues related to FDA Accelerated Approval Pathways

Bills named in this filing 4

H.R. 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
S. 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 932
Give Kids a Chance Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.